These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 589594)

  • 21. Teniposide in the treatment of non-small cell lung carcinoma.
    Giaccone G; Donadio M; Ferrati P; Bonardi G; Ciuffreda L; Bagatella M; Calciati A
    Cancer Treat Rep; 1987 Jan; 71(1):83-5. PubMed ID: 3024829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teniposide is not effective in chronic lymphocytic leukemia.
    Zagonel V; Tirelli U; Veronesi A; Galligioni E; Tumolo S; Roncadin M; Carbone A; Grigoletto E
    Blut; 1986 Jan; 52(1):59-61. PubMed ID: 3632912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of VM-26 in adult malignancies.
    Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
    Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
    Qazi R; Elson P; Khandekar JD
    Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia.
    Rosenstock JG; Donaldson MH
    Cancer Treat Rep; 1976 Mar; 60(3):265-7. PubMed ID: 1063066
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase II study of teniposide in small cell carcinoma of the lung.
    Pedersen AG; Bork E; Osterlind K; Dombernowsky P; Hansen HH
    Cancer Treat Rep; 1984 Oct; 68(10):1289-91. PubMed ID: 6098366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe hypertensive reactions to teniposide (VM-26) in infants with congenital leukemia.
    Shimizu H; Frankel LS; Culbert SJ
    Am J Pediatr Hematol Oncol; 1987; 9(3):239-41. PubMed ID: 3479027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of teniposide (VM-26) in multiple myeloma.
    Tirelli U; Carbone A; Zagonei V; Brema F; Veronesi A; Grigoletto E; Volpe R
    Am J Clin Oncol; 1985 Aug; 8(4):329-31. PubMed ID: 3909805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teniposide: a review of 12 years of experience.
    O'Dwyer PJ; Alonso MT; Leyland-Jones B; Marsoni S
    Cancer Treat Rep; 1984 Dec; 68(12):1455-66. PubMed ID: 6391663
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II study of teniposide in advanced breast cancer.
    Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
    Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total-body irradiation and high-dose teniposide: a pilot study in bone marrow transplantation for patients with relapsed acute lymphoblastic leukemia.
    Krance RA; Forman SJ; Blume KG
    Cancer Treat Rep; 1987 Jun; 71(6):645-7. PubMed ID: 3555790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination chemotherapy for patients with relapsed malignant lymphoma using methyl-GAG and teniposide (VM-26).
    Warrell RP; Straus DJ; Young CW
    Cancer Treat Rep; 1982 May; 66(5):1121-5. PubMed ID: 7044533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
    Jankowski RP; Vahrson H
    Med Klin; 1977 Dec; 72(49):2122-6. PubMed ID: 337083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of VM 26 (epipodophyllotoxin) in treating acute leukemias and lymphomas in the adult].
    Kondrat'eva NA; Gershanovich ML; Kondrat'ev VB; Lebedev VN; Vygovskaia IaI
    Probl Gematol Pereliv Krovi; 1981 Jul; 26(7):10-4. PubMed ID: 7279889
    [No Abstract]   [Full Text] [Related]  

  • 35. [Cytosine arabinoside and VM-26 in induction treatment, failures and recurrences of childhood acute lymphoblastic leukemias].
    Navajas Gutiérrez A; Bezanilla Regato JL; Moya Calderón E; Piñán MA
    An Esp Pediatr; 1988 Oct; 29 Suppl 34():91-3. PubMed ID: 3214046
    [No Abstract]   [Full Text] [Related]  

  • 36. Hypersensitivity reactions to teniposide (VM-26): an analysis.
    O'Dwyer PJ; King SA; Fortner CL; Leyland-Jones B
    J Clin Oncol; 1986 Aug; 4(8):1262-9. PubMed ID: 3525769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [VM-26 and cytosine arabinoside in the treatment of acute refractory lymphoblastic leukemia in adults].
    Marín P; Grañena A; Carreras E; Sierra J; Olivé MT; Rozman C
    Sangre (Barc); 1984; 29(4-A):399-404. PubMed ID: 6594782
    [No Abstract]   [Full Text] [Related]  

  • 38. VM 26 (4-demethyl-epipodophyllotoxin-beta-d-thenylidine glucoside) in the treatment of urinary bladder tumors.
    Mechl Z; Rovný F; Sopková B
    Neoplasma; 1977; 24(4):411-4. PubMed ID: 904743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroblastoma.
    Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
    Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
    van der Burg ME; ten Bokkel Huinink WW; Vriesendorp R; van Oosterom AT; Neijt JP; Vermorken JB; van Putten WL; Kooiman A
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):997-8. PubMed ID: 3666002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.